UNSPSC 51292106: Maprotiline hydrochloride

This classification denotes a tricyclic antidepressant with the molecular formula C20H23N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C8J54PVFI, chemically known as 9,10-ethanoanthracene-9(10h)-propylamine, n-methyl-, hydrochloride but more generally known as maprotiline hydrochloride, which bears US NIH Compound Identifier 71478. European Medicines Agency schedules Maprotiline hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03088MIG.

UNSPSC 51292106 Maprotiline hydrochloride, a Commodity code, nominally covers a specific antidepressant pharmaceutical, but recent state and local solicitations tagged under this code show minimal alignment with the specific drug name. The recent opportunities instead reflect broader pharmaceutical procurement activity spanning naloxone distribution systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and over-the-counter products. State and local buying under this code identifier centers on pharmaceutical supply chain management, wholesale distribution partnerships, and community health initiatives requiring bulk pharmaceutical procurement and quarterly or ongoing fulfillment.

Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local government facilities across multiple states including Oregon). Recent solicitations are geographically dispersed across Florida, Texas, and the Upper Midwest. Representative opportunities include Seminole County's IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries due July 26, 2023; the Texas HHS Commission's April 2026 RFI on direct-to-manufacturer prescription programs seeking vendor capabilities for self-insured health plan contracting; and the Minnesota MMCAP's March 2026 RFP for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, effective July 1, 2026. The MMCAP solicitation requires cGMP certification, Drug Supply Chain Security Act compliance, and pricing competitiveness weighted at 75 percent of evaluation. The code shows activity across health department procurement, cooperative purchasing consortia, and state pharmacy benefit program expansion, though the specific maprotiline commodity itself does not appear in the recent opportunities reviewed.